Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine plus carboplatin for treatment-resistant metastatic melanoma
ACTRN12616000440426Phase 2Terminated
- Sponsor
- University of Newcastle
- Start
- Feb 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine and carboplatin in melanoma, sponsored by University of Newcastle. Primary endpoints: Tumor methylation and XPC modulation and Tumor and blood immune-response markers. Started Feb 2017; status: terminated.
02
Drugs
decitabinecarboplatin
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12616000440426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000440426.